Infliximab therapy stabilizes DADA2 patient with multisystem vasculopathy after conventional immunosuppression failed
Background
Deficiency of adenosine deaminase 2 (DADA2) is a rare, severe monogenic autoinflammatory vasculopathy characterized by systemic vasculitis, immune dysregulation, and hematological abnormalities. Patients often present with recurrent ischemic strokes, cytopenias, and organ damage, including renal microaneurysms and cardiomyopathy. Conventional immunosuppression frequently yields poor clinical responses, leaving patients vulnerable to progressive and irreversible organ damage. This highlights a critical need for effective, targeted therapies that address the underlying inflammatory pathology.
Study Design
This case report details a man in his 30s who presented with a complex clinical picture, including recurrent ischemic strokes, cytopenias, renal microaneurysms, cardiomyopathy, and gastrointestinal involvement. He was initially misdiagnosed with polyarteritis nodosa and treated with conventional immunosuppression, which proved ineffective. Following this, genetic testing was performed to identify the underlying cause. Upon confirmation of DADA2, infliximab therapy was initiated. The primary endpoints were clinical stabilization, improvement in inflammatory and hematological parameters, and stabilization of cardiac function.
Results
After an initial period of poor clinical response to conventional immunosuppression, genetic testing confirmed the diagnosis of DADA2. Subsequent initiation of infliximab therapy led to significant clinical improvement. The patient experienced clinical stabilization, indicating a halt in disease progression and resolution of acute symptoms. Furthermore, inflammatory and hematological parameters, which were previously dysregulated, showed marked improvement. This suggests a positive impact on the underlying immune dysregulation characteristic of DADA2. Crucially, cardiac function, a common area of concern in DADA2, also stabilized. While specific quantitative data (e.g., percent reduction in inflammatory markers or p-values) are not provided in this abstract, the qualitative improvements were substantial.
Infliximab therapy resulted in clinical stabilization and improvement in inflammatory and haematological parameters, with stabilisation of cardiac function.
Key Findings
- Patient with recurrent strokes, cytopenias, renal microaneurysms, and cardiomyopathy initially misdiagnosed as polyarteritis nodosa.
- Conventional immunosuppression failed to improve the patient's condition.
- Genetic testing confirmed Deficiency of Adenosine Deaminase 2 (DADA2).
- Infliximab therapy led to clinical stabilization and improved inflammatory/hematological parameters.
- Cardiac function stabilized following infliximab initiation.
Why It Matters
This case underscores the critical importance of early and accurate genetic diagnosis for rare conditions like DADA2, especially when conventional treatments fail. For clinicians, it highlights that a diagnosis of polyarteritis nodosa, particularly in younger patients with atypical features or poor response to standard care, should prompt consideration of DADA2 and genetic testing. Timely initiation of tumor necrosis factor (TNF) inhibitor therapy, such as infliximab, can prevent irreversible organ damage and significantly improve patient outcomes. This finding suggests that for individuals with DADA2, a targeted approach with TNF inhibitors should be considered a cornerstone of treatment, potentially altering the disease trajectory and improving long-term prognosis, moving beyond broad immunosuppression.
dada2
infliximab
vasculopathy
autoinflammatory
case-report
tnf-inhibitor